ArticleJournal of anesthesia2025
An injectable controlled-release local anesthetic formulation of levobupivacaine based on a temperature-responsive polymer: Evaluation of analgesia, motor impairment, and histological toxicity in rats.
Article in Journal of anesthesia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposePostoperative pain management is extremely important for early recovery after surgery. However, effective and safe techniques for controlling postoperative pain are lacking. This study examined the effectiveness of controlled-release levobupivacaine for creating sciatic nerve blocks in a rat model of postoperative pain.
methodsA novel controlled-release injectable levobupivacaine gel was produced using a triblock copolymer of poly(ε-caprolactone-co-glycolide) and polyethylene glycol (tri-PCG). Male rats were used to create the incisional pain model. A single dose of controlled-release levobupivacaine (2.25%) gel, 0.25% levobupivacaine (clinical use), or tri-PCG was injected around the sciatic nerve of each rat immediately before paw incision. The pain thresholds were assessed preoperatively and up to 48 h postoperatively using von Frey filaments. Side effects were assessed using a motor impairment test, levobupivacaine blood level measurements, and pathological assessments.
resultsThe novel controlled-release levobupivacaine exhibited temperature-responsive sol-gel transition. In vitro, this formulation released 60% of its levobupivacaine content within 24 h. The withdrawal threshold was higher in the controlled-release levobupivacaine group than in the 0.25% levobupivacaine group at 6 and 12 h after paw incision. Motor impairment was not observed after controlled-release levobupivacaine injection, and the levobupivacaine blood level remained below the limit of detection throughout the assessment. On histopathology, weak signs of inflammation were detected in rat muscle and nerve tissues in the controlled-release levobupivacaine group.
conclusionA single injection of controlled-release levobupivacaine gel almost safely inhibited hyperalgesia for 12 h in a rat model. However, further research is needed on its effects on the surrounding tissue.
Indexed as
Identifiers
40188184What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.